Tandem Diabetes Care (TNDM) PT Raised to $140 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts TNDM Hot Sheet
Price: $17.69 -5.25%
Rating Summary:
19 Buy, 15 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 19 | New: 13
Rating Summary:
19 Buy, 15 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 19 | New: 13
Join SI Premium – FREE
Oppenheimer analyst Steven Lichtman raised the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $140.00 (from $135.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Essential Properties Realty Trust (EPRT) PT Lowered to $31 at Cantor Fitzgerald
- Napco Security Technologies, Inc. (NSSC) PT Lowered to $45 at DA Davidson
- Philip Morris (PM) PT Raised to $232 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
